TARRYTOWN, N.Y. and CAMBRIDGE, Mass., March 16, 2020 /PRNewswire/ — U.S. Phase 2/3 trial initiated and will begin enrolling patients immediately Regeneron is leading U.S. trials, Sanofi will lead upcoming ex-U.S. trials Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced they have started a clinical program evaluating Kevzara® (sarilumab) in patients hospitalized with severe COVID-19 infection. Kevzara is a fully-human monoclonal …